dc.contributor.author | Ömer Cevit | |
dc.contributor.author | Ruhiye Cevit | |
dc.contributor.author | Gökhan Köylüoğlu | |
dc.contributor.author | Dilara İçağasıoğlu | |
dc.contributor.author | Asım Gültekin | |
dc.contributor.author | Fatoş Tanzer | |
dc.date.accessioned | 23.07.201910:49:13 | |
dc.date.accessioned | 2019-07-23T16:19:55Z | |
dc.date.available | 23.07.201910:49:13 | |
dc.date.available | 2019-07-23T16:19:55Z | |
dc.date.issued | 1999 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.uri | http://www.trdizin.gov.tr/publication/paper/detail/T1RFNU1qST0= | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/1074 | |
dc.description.abstract | We investigated the effect of antibiotic or G-CSF plus antibiotic therapy given to E. coli septic rats. In our study, 80 rats were inoculated transperitoneally with 1 ml of a solution containing 10 7 colony forming units per milliliter of E. coli. Rats were divided into four treatment groups before being inoculaded with E. coli in a random fashion. Therapy was then started with cefotaxime (150 mg/kg intraperitonelally) and either Granulocyte-Colony Stimulation Factor (G-CSF; 30 µg/kg intarperitoneally) or placebo 24 hours after inoculation of E. coli for 3 consective days. Group A 1 , sepsis-antibiotics group, had a mortality rate of 65%; Group A 2 , sepsis+G-CSF plus antibiotics group, had a mortality rate of 40% (p>0.05); Group B1, neutropenic sepsis+antibiotics group, had a mortality rate of 85%; B 2 , neutropenic sepsis+G-CSF plus antibiotics group, had a mortality rate of 55% (p<0.05). By day 7 after E. coli incoculation, there was a significant difference in the mortality rate between the two neutropenic groups. No significant differences were found in the hemoglobin levels and thrombocyte counts between the groups but a significant increase in white blood cell (WBC) and absolute neutrophil counts (ANC) were found in the G-CSF treated groups. This study shows that administration of G-CSF, in addition to cefotaxime, in neutropenic rats with E. coli sepsis significantly decreased mortality rate compared with antibiotics alone. | en_US |
dc.description.abstract | We investigated the effect of antibiotic or G-CSF plus antibiotic therapy given to E. coli septic rats. In our study, 80 rats were inoculated transperitoneally with 1 ml of a solution containing 10 7 colony forming units per milliliter of E. coli. Rats were divided into four treatment groups before being inoculaded with E. coli in a random fashion. Therapy was then started with cefotaxime (150 mg/kg intraperitonelally) and either Granulocyte-Colony Stimulation Factor (G-CSF; 30 µg/kg intarperitoneally) or placebo 24 hours after inoculation of E. coli for 3 consective days. Group A 1 , sepsis-antibiotics group, had a mortality rate of 65%; Group A 2 , sepsis+G-CSF plus antibiotics group, had a mortality rate of 40% (p>0.05); Group B1, neutropenic sepsis+antibiotics group, had a mortality rate of 85%; B 2 , neutropenic sepsis+G-CSF plus antibiotics group, had a mortality rate of 55% (p<0.05). By day 7 after E. coli incoculation, there was a significant difference in the mortality rate between the two neutropenic groups. No significant differences were found in the hemoglobin levels and thrombocyte counts between the groups but a significant increase in white blood cell (WBC) and absolute neutrophil counts (ANC) were found in the G-CSF treated groups. This study shows that administration of G-CSF, in addition to cefotaxime, in neutropenic rats with E. coli sepsis significantly decreased mortality rate compared with antibiotics alone. | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Cerrahi | en_US |
dc.title | Administration of granulocyte colony stimulating factor (G-CSF) in experimentally infected rats | en_US |
dc.type | other | en_US |
dc.relation.journal | Turkish Journal of Medical Sciences | en_US |
dc.contributor.department | Sivas Cumhuriyet Üniversitesi | en_US |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.endpage | 112 | en_US |
dc.identifier.startpage | 109 | en_US |
dc.relation.publicationcategory | Diğer | en_US] |